CNCT News & Analysis

Century Therapeutics (CNCT) Price Target Raised on Diabetes Therapy Potential

H.C. Wainwright increased the price target for Century Therapeutics (CNCT) based on the company's promising developments in diabetes therapy. This adjustment highlights the evolving landscape of diabetes treatment and Century's potential role within it. While specific numbers related to the new price target were not disclosed, analyst interest may indicate confidence in the company's growth trajectory. This news could attract investor attention, potentially impacting CNCT's stock performance positively.